ASCO Guideline Update | ESR1 mutation testing for HR+/HER2- metastatic breast cancer therapy

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

Commentary: Guideline Update Provides New Testing and Treatment Recommendations for Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Mutations – ASCO Daily News